Literature DB >> 8603406

Dual action of tirapazamine in the induction of DNA strand breaks.

G D Jones1, M Weinfeld.   

Abstract

Tirapazamine (3-amino-1,2,4-benzotriazine-1,4-dioxide, SR 4233) is the lead compound of a new class of hypoxic cell cytotoxins showing considerable antitumor activity. Hypoxic cytotoxicity of tirapazamine is believed to be mediated by free radical attack of its one-electron reduced metabolite on DNA, but little is known about the DNA lesions induced by the drug. Using the anoxic xanthine/xanthine oxidase system to effect one-electron reduction of tirapazamine under controlled conditions, we studied the action of the drug toward pUC18 and calf thymus DNA. Agarose gel electrophoresis indicated that tirapazamine causes substantially higher levels of single-strand breakage than double-stand breakage. The 5' DNA termini at the single-strand breaks were shown to be phosphorylated. Little, if any, base damage was observed when the damaged DNA was analyzed by a 32P-postlabeling assay. The major detectable lesion (comprising approximately 32% of the 3' ends of tirapazamine-induced single-strand breaks) was the phosphoglycolate moiety, which is caused by deoxyribose fragmentation. Since phosphoglycolate formation requires the addition of oxygen, we conclude that tirapazamine acts in a dual fashion to produce phosphoglycolates: (a) to generate a free radical in the deoxyribose ring (i.e., .C-4' and (b) then to donate an oxygen atom. The oxygen donation by tirapazamine was confirmed by anoxic irradiation of DNA in the presence of the unmetabolized drug. Increasing the concentration of the drug (up to 50 microM) led to a dramatic increase in the yield of phosphoglycolate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603406

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors.

Authors:  N K Bernstein; F Karimi-Busheri; A Rasouli-Nia; R Mani; G Dianov; J N M Glover; M Weinfeld
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

Review 2.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

3.  Enzymatic conversion of 6-nitroquinoline to the fluorophore 6-aminoquinoline selectively under hypoxic conditions.

Authors:  Anuruddha Rajapakse; Collette Linder; Ryan D Morrison; Ujjal Sarkar; Nathan D Leigh; Charles L Barnes; J Scott Daniels; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2013-04-02       Impact factor: 3.739

4.  A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates.

Authors:  Dmitri Zagorevskii; Minghu Song; Curt Breneman; Yang Yuan; Tarra Fuchs; Kent S Gates; C Michael Greenlief
Journal:  J Am Soc Mass Spectrom       Date:  2003-08       Impact factor: 3.109

5.  Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.

Authors:  J C Doloff; N Khan; J Ma; E Demidenko; H M Swartz; Y Jounaidi
Journal:  Curr Cancer Drug Targets       Date:  2009-09       Impact factor: 3.428

6.  DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

Authors:  Goutam Chowdhury; Venkatraman Junnotula; J Scott Daniels; Marc M Greenberg; Kent S Gates
Journal:  J Am Chem Soc       Date:  2007-09-27       Impact factor: 15.419

7.  Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.

Authors:  Venkatraman Junnotula; Ujjal Sarkar; Sarmistha Sinha; Kent S Gates
Journal:  J Am Chem Soc       Date:  2009-01-28       Impact factor: 15.419

8.  Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Authors:  Kevin M Johnson; Zachary D Parsons; Charles L Barnes; Kent S Gates
Journal:  J Org Chem       Date:  2014-07-25       Impact factor: 4.354

9.  Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models.

Authors:  Manal Mehibel; Yu Xu; Caiyun G Li; Eui Jung Moon; Kaushik N Thakkar; Anh N Diep; Ryan K Kim; Joshua D Bloomstein; Yiren Xiao; Julien Bacal; Joshua C Saldivar; Quynh-Thu Le; Karlene A Cimprich; Erinn B Rankin; Amato J Giaccia
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.